Person Health is building a more preventive future — a health intelligence platform combining differentiated diagnostics, person-centered data, and guided engagement to identify meaningful health risks earlier.
Not fragmented across tests, visits, and portals — connected, so what matters can surface sooner.
Person Health reads multiple health signals as one connected picture — turning scattered information into clearer information centered on the person.
Once the platform recognizes patterns in one disease, new areas can be developed on the same system — not rebuilt from scratch.
We read the broader molecular pattern — not a single marker — so the platform can recognize changes narrow signals may miss.
Our products are the current expressions of that platform. The infrastructure, intelligence, and integration are the larger story.
Earlier insight changes everything. Blood-based molecular fingerprinting, beginning with breast cancer research — launching for Research Use Only.
A person-centered place to access testing, organize health information, and engage with guided health intelligence.
A differentiated, non-invasive breath platform — a future source of earlier signals as the platform expands.
Differentiated blood and breath technologies designed to identify patterns associated with health and disease.
Health information brought together through a governed, person-centered health-intelligence environment.
Clearer information that helps people and clinicians understand what may deserve attention.
“As a cancer survivor, I know how quickly disease can change a life — and how much earlier knowledge can matter.”
That experience shaped the mission behind Person Health: disease should never be a surprise. This is bigger than one story — we've brought together an experienced team to help people and their clinicians recognize meaningful risks earlier.
An experienced team across molecular diagnostics, medical devices, laboratory testing, software, artificial intelligence, clinical care, and commercialization.
Let's talk while
it's still early.
We're in early conversations with a select group of clinicians, researchers, and partners who want to help recognize disease earlier. If that's you, we'd like to meet.